JP2006510618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006510618A5 JP2006510618A5 JP2004553852A JP2004553852A JP2006510618A5 JP 2006510618 A5 JP2006510618 A5 JP 2006510618A5 JP 2004553852 A JP2004553852 A JP 2004553852A JP 2004553852 A JP2004553852 A JP 2004553852A JP 2006510618 A5 JP2006510618 A5 JP 2006510618A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- phenyl
- pain
- oxo
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 52
- 208000002193 Pain Diseases 0.000 claims 33
- 230000036407 pain Effects 0.000 claims 29
- 239000000651 prodrug Substances 0.000 claims 28
- 229940002612 prodrug Drugs 0.000 claims 28
- 150000003839 salts Chemical class 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 206010002091 Anaesthesia Diseases 0.000 claims 12
- 230000037005 anaesthesia Effects 0.000 claims 12
- 230000037396 body weight Effects 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- BEQZHFIKTBVCAU-LBPRGKRZSA-N (2s)-2-amino-2-(2-chlorophenyl)cyclohexan-1-one Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(N)CCCCC1=O BEQZHFIKTBVCAU-LBPRGKRZSA-N 0.000 claims 8
- BEQZHFIKTBVCAU-UHFFFAOYSA-N 2-amino-2-(2-chlorophenyl)-1-cyclohexanone Chemical compound C=1C=CC=C(Cl)C=1C1(N)CCCCC1=O BEQZHFIKTBVCAU-UHFFFAOYSA-N 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 230000003444 anaesthetic effect Effects 0.000 claims 8
- 230000000202 analgesic effect Effects 0.000 claims 8
- 229960003299 ketamine Drugs 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 7
- LNJROULPSUMIKM-UHFFFAOYSA-N benzyl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound ClC1=CC=CC=C1C1(NC(=O)OCC=2C=CC=CC=2)C(=O)CCCC1 LNJROULPSUMIKM-UHFFFAOYSA-N 0.000 claims 5
- HCZIRBMTVSUBQG-UHFFFAOYSA-N butyl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C1(NC(=O)OCCCC)CCCCC1=O HCZIRBMTVSUBQG-UHFFFAOYSA-N 0.000 claims 5
- JSMLYOVUWZPMRT-UHFFFAOYSA-N ethyl 2-[[1-(2-chlorophenyl)-2-oxocyclohexyl]amino]acetate Chemical compound C=1C=CC=C(Cl)C=1C1(NCC(=O)OCC)CCCCC1=O JSMLYOVUWZPMRT-UHFFFAOYSA-N 0.000 claims 5
- NFEDRUZLYVEQFI-UHFFFAOYSA-N ethyl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C1(NC(=O)OCC)CCCCC1=O NFEDRUZLYVEQFI-UHFFFAOYSA-N 0.000 claims 5
- VRURQRAMHBAFOK-UHFFFAOYSA-N phenyl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound ClC1=CC=CC=C1C1(NC(=O)OC=2C=CC=CC=2)C(=O)CCCC1 VRURQRAMHBAFOK-UHFFFAOYSA-N 0.000 claims 5
- BJHGQFPMVBHYLW-UHFFFAOYSA-N propan-2-yl n-[1-(2-chlorophenyl)-2-oxocyclohexyl]carbamate Chemical compound C=1C=CC=C(Cl)C=1C1(NC(=O)OC(C)C)CCCCC1=O BJHGQFPMVBHYLW-UHFFFAOYSA-N 0.000 claims 5
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims 4
- 208000000003 Breakthrough pain Diseases 0.000 claims 4
- 208000000094 Chronic Pain Diseases 0.000 claims 4
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims 4
- 230000035606 childbirth Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 208000021722 neuropathic pain Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- -1 azaaryl Chemical group 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000002270 dispersing agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 239000007975 buffered saline Substances 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000008223 sterile water Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42679302P | 2002-11-18 | 2002-11-18 | |
| PCT/US2003/036789 WO2004045601A1 (en) | 2002-11-18 | 2003-11-18 | Analgesic uses of norketamine and ketamine/norketamine prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006510618A JP2006510618A (ja) | 2006-03-30 |
| JP2006510618A5 true JP2006510618A5 (enExample) | 2007-01-25 |
Family
ID=32326427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553852A Withdrawn JP2006510618A (ja) | 2002-11-18 | 2003-11-18 | ノルケタミンおよびケタミン／ノルケタミンプロドラッグの鎮痛的使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040248964A1 (enExample) |
| EP (2) | EP1567145B1 (enExample) |
| JP (1) | JP2006510618A (enExample) |
| AT (1) | ATE432697T1 (enExample) |
| AU (1) | AU2003291037A1 (enExample) |
| CA (1) | CA2506615A1 (enExample) |
| DE (1) | DE60327883D1 (enExample) |
| NZ (1) | NZ540282A (enExample) |
| WO (1) | WO2004045601A1 (enExample) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0523031D0 (en) * | 2005-11-11 | 2005-12-21 | Yaupon Therapeutics | Enhancement of morphine analgesia by s(-)-norketamine |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8252328B2 (en) | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| US8357114B2 (en) | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
| US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
| US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US8865743B2 (en) | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US9066847B2 (en) | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
| US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
| US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
| US20070260491A1 (en) * | 2006-05-08 | 2007-11-08 | Pamela Palmer | System for delivery and monitoring of administration of controlled substances |
| WO2009131794A1 (en) * | 2008-03-27 | 2009-10-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| CN102223791A (zh) | 2008-09-27 | 2011-10-19 | 塔阿克斯有限公司 | 用于神经病变治疗的局部用制剂 |
| US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
| EP2454226B1 (en) * | 2009-07-16 | 2017-03-22 | Solvay Fluor GmbH | Process for the preparation of fluoroalkyl (fluoro)alkyl carbonates |
| JP6296985B2 (ja) * | 2011-10-14 | 2018-03-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用 |
| US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
| WO2014020155A1 (en) * | 2012-08-02 | 2014-02-06 | Clinpharm Reform Gmbh | Oral transmucosal adminstration forms of s-ketamine |
| MX2015004362A (es) | 2012-10-08 | 2015-12-08 | Auckland Uniservices Ltd | Derivados de ketamina. |
| PE20200404A1 (es) | 2013-03-15 | 2020-02-26 | Janssen Pharmaceutica Nv | Composicion farmaceutica de clorhidrato de s-ketamina |
| EP2983787B1 (en) | 2013-04-12 | 2019-10-02 | Icahn School of Medicine at Mount Sinai | Method for treating post-traumatic stress disorder |
| WO2015037248A1 (en) | 2013-09-13 | 2015-03-19 | National University Corporation Chiba University | Application of r-ketamine and salt thereof as pharmaceuticals |
| WO2015101693A1 (es) * | 2013-12-31 | 2015-07-09 | Servicio Andaluz De Salud | Composiciones y preparaciones combinadas para el tratamiento de las algias orofaríngeas |
| US9610259B2 (en) | 2014-01-14 | 2017-04-04 | Children's Hospital Medical Center | Compositions and methods for treating an autism spectrum disorder |
| KR20170054470A (ko) | 2014-09-15 | 2017-05-17 | 얀센 파마슈티카 엔.브이. | VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법 |
| EP3215147B1 (en) | 2014-11-04 | 2024-02-28 | ACADIA Pharmaceuticals Inc. | Neuro-attenuating norketamine compounds and methods |
| WO2016106329A1 (en) | 2014-12-23 | 2016-06-30 | Acelrx Pharmaceuticals, Inc. | Systems, devices and methods for dispensing oral transmucosal dosage forms |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| WO2016186968A1 (en) * | 2015-05-15 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating motor disorders |
| EP3310439B1 (en) * | 2015-06-19 | 2024-05-29 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions for anesthesiological applications comprising benzodiazepine and ketamine |
| AU2016288188B2 (en) | 2015-06-27 | 2021-08-05 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US11111210B2 (en) | 2015-11-18 | 2021-09-07 | Spirify Pharma Inc. | Phenyl cyclohexanone derivatives and methods of making and using them |
| US11827606B2 (en) | 2015-11-18 | 2023-11-28 | Spirify Pharma Inc. | Phenyl cyclohexanone derivatives and methods of making and using them |
| WO2017087594A1 (en) | 2015-11-19 | 2017-05-26 | Biohaven Pharmaceutical Holding Company Ltd. | Amine prodrugs of pharmaceutical compounds |
| US11006661B2 (en) * | 2016-08-15 | 2021-05-18 | Mamood Valadi | Cigarette-like device for administration of substances |
| CA3034885A1 (en) * | 2016-08-31 | 2018-03-08 | Dart Neuroscience, Llc | Hydroxynorketamine derivatives for the treatment of disorders |
| US9963435B2 (en) | 2016-08-31 | 2018-05-08 | Dart Neuroscience, Llc | Compounds for therapeutic use |
| IL315066A (en) * | 2016-10-27 | 2024-10-01 | Univ Chiba Nat Univ Corp | Application of (s)-norketamine and salt therof as pharmaceutical |
| WO2019033330A1 (en) | 2017-08-17 | 2019-02-21 | Xw Laboratories, Inc. | PREPARATION AND USES OF DERIVATIVES TRACERS OF OXYGEN REACTIVE SPECIES |
| EP3988561B1 (en) | 2017-09-04 | 2023-06-07 | XWPharma Ltd. | Preparation and use of reactive oxygen species scavenger |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| TW201919595A (zh) * | 2017-09-27 | 2019-06-01 | 國立大學法人千葉大學 | 作為神經變性疾病或認知機能障礙之預防或治療劑之r-氯胺酮及其衍生物 |
| IL275482B1 (en) | 2017-12-22 | 2025-03-01 | Janssen Pharmaceuticals Inc | Esketamine for the treatment of depression |
| EP3505157B1 (en) | 2017-12-29 | 2021-12-08 | Celon Pharma S.A. | Dry powder ketamine composition for pulmonary administration in treatment-resistant depression |
| RU2756512C1 (ru) * | 2018-01-10 | 2021-10-01 | ЭксДабл-ЮФАРМА ЛТД. | Пролекарства кетамина, его композиции и применения |
| EP3753557B1 (en) | 2018-02-15 | 2025-11-05 | National University Corporation Chiba University | Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases |
| EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | Methods of treating substance abuse |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| WO2020237747A1 (zh) * | 2019-05-24 | 2020-12-03 | 北京大学深圳研究生院 | 一种长效化合物在制备药物中的应用 |
| US11753378B2 (en) * | 2021-04-19 | 2023-09-12 | Zevra Therapeutics, Inc. | Ketamine compounds and processes for making and using them |
| US11690811B2 (en) | 2021-08-13 | 2023-07-04 | XWPharma Ltd. | Pharmaceutical compositions and oral dosage forms of ketamine derivatives |
| EP4289815A1 (en) | 2022-06-10 | 2023-12-13 | Pcas | Crystalline forms of norketamine |
| WO2024044355A2 (en) * | 2022-08-25 | 2024-02-29 | 1/1The Trustees Of Columbia University In The City Of New York | Compositions and methods for the treatment of alzheimer's disease and other neurogenerative disease |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5407A (en) | 1847-12-28 | Fence | ||
| US713A (en) | 1838-04-25 | Improvement in many-chambered-cylinder fire-arms | ||
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4879119A (en) | 1984-02-21 | 1989-11-07 | Yamanouchi Pharmaceutical Co., Ltd. | Patch |
| US4671953A (en) | 1985-05-01 | 1987-06-09 | University Of Utah Research Foundation | Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| ATE107176T1 (de) | 1989-12-04 | 1994-07-15 | Searle & Co | System zur transdermalen albuterol applikation. |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| ATE132381T1 (de) | 1992-01-29 | 1996-01-15 | Voelkl Franz Ski | Ballspielschläger, insbesondere tennisschläger |
| SE9203743D0 (sv) | 1992-12-11 | 1992-12-11 | Astra Ab | Efficient use |
| US5543434A (en) * | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| ES2237767T3 (es) | 1995-04-14 | 2005-08-01 | Nektar Therapeutics | Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada. |
| CA2230690C (en) * | 1995-08-30 | 2008-12-23 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
| US6248789B1 (en) | 1996-08-29 | 2001-06-19 | Stuart L. Weg | Administration of ketamine to manage pain and to reduce drug dependency |
| CA2270531C (en) * | 1996-11-05 | 2011-08-30 | Head Explorer Aps | A method for treating tension-type headache |
| AU756136B2 (en) | 1997-06-23 | 2003-01-02 | Queen's University At Kingston | Microdose therapy |
| US6630169B1 (en) | 1999-03-31 | 2003-10-07 | Nektar Therapeutics | Particulate delivery systems and methods of use |
| US6406745B1 (en) | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
| US6565888B1 (en) | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
| US20050148673A1 (en) * | 2002-07-11 | 2005-07-07 | Harbut Ronald E. | Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition |
-
2003
- 2003-11-18 WO PCT/US2003/036789 patent/WO2004045601A1/en not_active Ceased
- 2003-11-18 JP JP2004553852A patent/JP2006510618A/ja not_active Withdrawn
- 2003-11-18 DE DE60327883T patent/DE60327883D1/de not_active Expired - Fee Related
- 2003-11-18 AT AT03783623T patent/ATE432697T1/de not_active IP Right Cessation
- 2003-11-18 NZ NZ540282A patent/NZ540282A/en unknown
- 2003-11-18 AU AU2003291037A patent/AU2003291037A1/en not_active Abandoned
- 2003-11-18 EP EP03783623A patent/EP1567145B1/en not_active Expired - Lifetime
- 2003-11-18 EP EP08168894A patent/EP2027854A1/en not_active Withdrawn
- 2003-11-18 CA CA002506615A patent/CA2506615A1/en not_active Abandoned
- 2003-11-18 US US10/714,643 patent/US20040248964A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006510618A5 (enExample) | ||
| EP1567145B1 (en) | Analgesic uses of (s)-norketamine | |
| RU2438660C2 (ru) | Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей | |
| RU2317294C2 (ru) | (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора | |
| JP2006503850A5 (enExample) | ||
| JP2007507494A5 (enExample) | ||
| JP2003509349A5 (enExample) | ||
| JP2013511496A5 (enExample) | ||
| JP2004514663A5 (enExample) | ||
| JP2001526218A5 (enExample) | ||
| RU2009111388A (ru) | Органические соединения | |
| JP2013508279A5 (enExample) | ||
| JP2008510758A5 (enExample) | ||
| ES3037078T3 (en) | Isoxazoline compounds for use in treating demodicosis | |
| CA2303815A1 (en) | N,n-bis (phenylcarbamoylmethyl) dimethylammonium chloride and derivatives in the treatment of pain | |
| JP2012523395A5 (enExample) | ||
| JP2003519228A5 (enExample) | ||
| JP2007515476A5 (enExample) | ||
| RU2002101622A (ru) | Нафтохиноновые производные и их использование для лечения и борьбы с туберкулезом | |
| CA2688542C (en) | Methods and compositions for administration of oxybutynin | |
| JP2005531612A (ja) | ネフォパムの製剤および痛みの治療におけるその使用 | |
| RU2004133387A (ru) | Фармацевтический препарат с немедленным высвобождением | |
| JP2002544227A5 (enExample) | ||
| JP2022508217A (ja) | Ｔａｓｋ－１およびｔａｓｋ－３チャンネル阻害剤を含有する医薬投薬形態の製造方法、ならびに呼吸障害治療におけるその使用 | |
| RU2008108175A (ru) | Комбинация соединений, которые можно использовать при лечении респираторных заболеваний, особенно хронической оструктивной болезни легких (copo) и астмы |